| Drug | Ursodeoxycholic Acid (UDCA) |
|---|---|
| CAS | 128-13-2 |
| PBC Dose | 13–15 mg/kg/day, divided doses |
| PBC Status | FDA-approved first-line therapy |
| PSC Dose | 13–15 mg/kg/day (standard); high-dose unsafe |
| ICP Dose | 10–20 mg/kg/day (off-label) |
| Key Guidelines | AASLD, EASL, ACG |
Ursodeoxycholic acid (UDCA) has a firmly established role as first-line pharmacotherapy for primary biliary cholangitis, and a more complex evidence base across other hepatobiliary conditions. This article reviews the clinical trial data and guideline recommendations for UDCA across four liver disease indications: PBC, PSC, NASH/NAFLD, and intrahepatic cholestasis of pregnancy.
Primary biliary cholangitis (formerly primary biliary cirrhosis) is a chronic, progressive autoimmune liver disease characterized by T-cell-mediated destruction of small intrahepatic bile ducts, leading to cholestasis, fibrosis, and eventually cirrhosis. PBC predominantly affects middle-aged women (female-to-male ratio approximately 9:1), with an estimated global incidence of 2–4 per 100,000 person-years. Without treatment, the median time from diagnosis to end-stage liver disease is approximately 10–15 years.
UDCA at a dose of 13–15 mg/kg/day is the FDA-approved first-line treatment for PBC, endorsed by the AASLD and EASL practice guidelines. The landmark 1991 randomized trial by Poupon et al. (n=146) demonstrated that UDCA improved serum biochemistries. Subsequently, three large randomized controlled trials — the Mayo Clinic trial (Lindor, 1994, n=180), the Canadian multicenter trial (Heathcote, 1994, n=222), and the French trial (Poupon, 1994, n=152) — together demonstrated that UDCA reduced serum alkaline phosphatase, ALT, gamma-GT, and bilirubin, and delayed histological progression. A combined analysis by Poupon et al. in 1997 (n=548 patients from the three trials) showed that UDCA delayed the time to death or liver transplantation in patients with moderate-to-severe PBC (baseline bilirubin > 1.4 mg/dL or histologic stage III/IV).
Not all PBC patients respond equivalently to UDCA. Biochemical response is assessed after 6–12 months of therapy using validated criteria. The Paris-I criteria define an adequate response as serum bilirubin ≤ 1 mg/dL (17 μmol/L), alkaline phosphatase ≤ 3x ULN, and AST ≤ 2x ULN after one year of UDCA therapy. Patients meeting these criteria have a transplant-free survival equivalent to that of the general population. Approximately 60–70% of PBC patients achieve an adequate biochemical response with UDCA alone. For the 30–40% who do not, second-line agents such as obeticholic acid (OCA) or fibrates (bezafibrate, fenofibrate) are recommended as add-on therapy under current AASLD and EASL guidance.
UDCA is administered at 13–15 mg/kg/day in two or three divided doses with food. The total daily dose for a 70 kg patient is 910–1050 mg. Liver biochemistry (alkaline phosphatase, ALT, gamma-GT, bilirubin, albumin) should be measured at baseline, at 3 and 6 months of treatment initiation, and every 6–12 months thereafter. UDCA is generally well tolerated in PBC patients over decades of continuous therapy. Weight gain (2–3 kg in the first year) has been reported in some studies but is usually mild.
UDCA's role in PSC is fundamentally different from PBC and remains controversial. PSC is characterized by multifocal bile duct strictures and progressive fibrosis, and is strongly associated with inflammatory bowel disease (60–80% of PSC patients have concurrent ulcerative colitis). No medical therapy has been proven to alter the natural history of PSC in a definitive randomized controlled trial.
Standard-dose UDCA (13–15 mg/kg/day) has been evaluated in multiple PSC studies. A 2001 trial by Lindor et al. randomized 105 PSC patients to UDCA 13–15 mg/kg/day vs placebo for 2 years and found statistically significant improvements in alkaline phosphatase and gamma-GT but no difference in the primary endpoint of histological progression or time to treatment failure. A 2017 Cochrane systematic review concluded that UDCA improved liver biochemistries but did not demonstrate a statistically significant effect on mortality, liver transplantation, or progression of PSC.
High-dose UDCA (28–30 mg/kg/day) is contraindicated in PSC. A 2009 trial by Lindor et al. randomized 150 PSC patients to high-dose UDCA vs placebo and found a statistically significant increase in the composite endpoint of death, liver transplantation, development of varices, ascites, or progression to cirrhosis in the UDCA arm (hazard ratio 2.3 for UDCA vs placebo; p=0.01). The mechanisms underlying this adverse outcome are not fully understood but may relate to high UDCA concentrations in the colon promoting the formation of lithocholic acid, or to acceleration of existing bile acid injury in obstructed ducts. Regardless, high-dose UDCA should never be used in PSC outside of an approved clinical trial.
Current AASLD guidelines do not recommend UDCA as standard therapy for PSC. Some hepatologists use standard-dose UDCA in selected patients with the goal of improving serum liver enzyme levels, but the practice is not evidence-based for hard clinical outcomes. Any use of UDCA in PSC should be at standard dose (13–15 mg/kg/day) and accompanied by a clear discussion of the limited evidence for benefit.
Non-alcoholic fatty liver disease (NAFLD) and its inflammatory form, non-alcoholic steatohepatitis (NASH), affect approximately 25% of the global adult population. UDCA has been evaluated in multiple NAFLD/NASH trials at doses of 13–15 mg/kg/day, typically for 12–24 months. While UDCA consistently reduces serum ALT levels (by approximately 20–30% from baseline), histological improvement (the gold standard in NASH trials) has not been consistently demonstrated. A 2011 meta-analysis by Musso et al. found that UDCA improved liver biochemistry and steatosis in some studies, but the overall effect on hepatocyte ballooning and fibrosis was not statistically significant across pooled data.
At present, UDCA is not a licensed or guideline-recommended treatment for NAFLD or NASH. Investigational use continues in certain settings, and UDCA is occasionally employed off-label for NASH patients with prominent cholestatic features who are not candidates for clinical trials or vitamin E/pioglitazone therapy. The higher doses evaluated in PBC and gallstone dissolution provide insufficient hepatoprotective benefit in NASH to warrant routine use.
ICP is a pregnancy-specific cholestatic disorder that typically presents in the second or third trimester with pruritus and elevated serum bile acids. It is associated with an increased risk of preterm birth, meconium-stained amniotic fluid, fetal distress, and stillbirth when total fasting serum bile acids exceed 40–100 μmol/L. UDCA at 10–20 mg/kg/day in divided doses has become the first-line pharmacotherapy for ICP, used extensively in clinical practice for over two decades despite being off-label for this indication in the United States.
A 2019 meta-analysis by Bacq et al. (including 23 studies, n=2,331) found that UDCA significantly reduced maternal pruritus, normalized serum ALT and bile acid levels, and was associated with a lower rate of preterm birth compared with placebo/no treatment. A large 2002 trial by Palma et al. showed that UDCA 15 mg/kg/day for 3 weeks improved pruritus in 77% of ICP patients vs 28% with placebo, and delivery occurred closer to term (mean 38.0 vs 36.7 weeks). The safety profile of UDCA in pregnancy is well characterized: fetal UDCA levels are low (2–4% of maternal serum levels), and no increased risk of congenital malformations or adverse fetal outcomes has been identified.
| Liver Disease | UDCA Dose | Guideline Status | Key Caveats |
|---|---|---|---|
| PBC | 13–15 mg/kg/day | First-line, FDA-approved | Assess biochemical response at 6–12 months; 30–40% incomplete responders may need second-line therapy |
| PSC | 13–15 mg/kg/day (if used) | Not recommended routinely; controversial | Improves liver biochemistries but not survival. High-dose (28–30 mg/kg) contraindicated due to harm. |
| NAFLD/NASH | 13–15 mg/kg/day | Not recommended; experimental | Reduces ALT but no consistent histological benefit; not a licensed treatment |
| ICP | 10–20 mg/kg/day | First-line (off-label) | Reduces pruritus, improves liver enzymes, may reduce preterm birth risk. Well-established pregnancy safety. |
UDCA remains the cornerstone of PBC treatment with well-documented long-term benefits in delaying histological progression and death or liver transplantation in biochemical responders. Its role in PSC and NAFLD/NASH is far less established and should not be assumed by extrapolation from the PBC evidence base. ICP represents a well-established off-label use with a favorable risk-benefit profile supported by two decades of clinical experience.